A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM

NCT05680129 · Completed

Last updated 2026-05-28

This clinical trial is testing the drug XW003 against dulaglutide in adults with type 2 diabetes to see how it affects their blood sugar levels over time.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 623 people

Who can join Ages 18–75 · all sexes

Timeline Started 2023-01 · est. completion 2024-10

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT05680129 ↗

Description as written by the study sponsor.

The aim of the study is to compare the efficacy and safety of two XW003 doses versus dulaglutide as add-on therapy to metformin in participants with type 2 diabetes mellitus (T2DM)

Treatments tested

Ecnoglutide high dosage also known as XW003 Drug

Administered subcutaneously
Ecnoglutide low dosage also known as XW003 Drug

Administered subcutaneously
Dulaglutide Drug

Administered subcutaneously
Metformin Drug

Administered orally

Main thing measured	Change from baseline in HbA1c
Sponsor	Hangzhou Sciwind Biosciences Co., Ltd.
Conditions studied	T2DM, Type 2 Diabetes Mellitus
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05680129 ↗